Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

DeepSNP: An End-to-End Deep Neural Network with Attention-Based Localization for Breakpoint Detection in Single-Nucleotide Polymorphism Array Genomic Data.

Eghbal-Zadeh H, Fischer L, Popitsch N, Kromp F, Taschner-Mandl S, Gerber T, Bozsaky E, Ambros PF, Ambros IM, Widmer G, Moser BA.

J Comput Biol. 2019 Jun;26(6):572-596. doi: 10.1089/cmb.2018.0172. Epub 2018 Dec 26.

PMID:
30585743
2.

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.

Berbegall AP, Bogen D, Pötschger U, Beiske K, Bown N, Combaret V, Defferrari R, Jeison M, Mazzocco K, Varesio L, Vicha A, Ash S, Castel V, Coze C, Ladenstein R, Owens C, Papadakis V, Ruud E, Amann G, Sementa AR, Navarro S, Ambros PF, Noguera R, Ambros IM.

Br J Cancer. 2018 May;118(11):1502-1512. doi: 10.1038/s41416-018-0098-6. Epub 2018 May 14.

3.

Detailed Protocols for the Isolation, Culture, Enrichment and Immunostaining of Primary Human Schwann Cells.

Weiss T, Taschner-Mandl S, Ambros PF, Ambros IM.

Methods Mol Biol. 2018;1739:67-86. doi: 10.1007/978-1-4939-7649-2_5.

PMID:
29546701
4.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.

5.

Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression.

Rifatbegovic F, Frech C, Abbasi MR, Taschner-Mandl S, Weiss T, Schmidt WM, Schmidt I, Ladenstein R, Ambros IM, Ambros PF.

Int J Cancer. 2018 Jan 15;142(2):297-307. doi: 10.1002/ijc.31053. Epub 2017 Oct 4.

6.

Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone.

Abbasi MR, Rifatbegovic F, Brunner C, Mann G, Ziegler A, Pötschger U, Crazzolara R, Ussowicz M, Benesch M, Ebetsberger-Dachs G, Chan GCF, Jones N, Ladenstein R, Ambros IM, Ambros PF.

Clin Cancer Res. 2017 Aug 1;23(15):4224-4232. doi: 10.1158/1078-0432.CCR-16-2082. Epub 2017 Feb 22.

7.

DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma.

Sheffield NC, Pierron G, Klughammer J, Datlinger P, Schönegger A, Schuster M, Hadler J, Surdez D, Guillemot D, Lapouble E, Freneaux P, Champigneulle J, Bouvier R, Walder D, Ambros IM, Hutter C, Sorz E, Amaral AT, de Álava E, Schallmoser K, Strunk D, Rinner B, Liegl-Atzwanger B, Huppertz B, Leithner A, de Pinieux G, Terrier P, Laurence V, Michon J, Ladenstein R, Holter W, Windhager R, Dirksen U, Ambros PF, Delattre O, Kovar H, Bock C, Tomazou EM.

Nat Med. 2017 Mar;23(3):386-395. doi: 10.1038/nm.4273. Epub 2017 Jan 30.

8.

Proteomics and transcriptomics of peripheral nerve tissue and cells unravel new aspects of the human Schwann cell repair phenotype.

Weiss T, Taschner-Mandl S, Bileck A, Slany A, Kromp F, Rifatbegovic F, Frech C, Windhager R, Kitzinger H, Tzou CH, Ambros PF, Gerner C, Ambros IM.

Glia. 2016 Dec;64(12):2133-2153. doi: 10.1002/glia.23045. Epub 2016 Aug 22.

PMID:
27545331
9.

Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors.

Brunner C, Brunner-Herglotz B, Ziegler A, Frech C, Amann G, Ladenstein R, Ambros IM, Ambros PF.

PLoS One. 2016 Aug 25;11(8):e0161369. doi: 10.1371/journal.pone.0161369. eCollection 2016.

10.

Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.

Araki A, Chocholous M, Gojo J, Dorfer C, Czech T, Heinzl H, Dieckmann K, Ambros IM, Ambros PF, Slavc I, Haberler C.

Acta Neuropathol Commun. 2016 Aug 22;4(1):88. doi: 10.1186/s40478-016-0349-9.

11.

The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.

Bogen D, Brunner C, Walder D, Ziegler A, Abbasi R, Ladenstein RL, Noguera R, Martinsson T, Amann G, Schilling FH, Ussowicz M, Benesch M, Ambros PF, Ambros IM.

Int J Cancer. 2016 Jul 1;139(1):153-63. doi: 10.1002/ijc.30050. Epub 2016 Mar 22.

12.

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.

Taschner-Mandl S, Schwarz M, Blaha J, Kauer M, Kromp F, Frank N, Rifatbegovic F, Weiss T, Ladenstein R, Hohenegger M, Ambros IM, Ambros PF.

Oncotarget. 2016 Jan 19;7(3):3571-86. doi: 10.18632/oncotarget.6527.

13.

Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Berbegall AP, Villamón E, Piqueras M, Tadeo I, Djos A, Ambros PF, Martinsson T, Ambros IM, Cañete A, Castel V, Navarro S, Noguera R.

Oncogene. 2016 Mar 17;35(11):1423-32. doi: 10.1038/onc.2015.200. Epub 2015 Jun 29.

PMID:
26119945
14.

Bone marrows from neuroblastoma patients: an excellent source for tumor genome analyses.

Abbasi MR, Rifatbegovic F, Brunner C, Ladenstein R, Ambros IM, Ambros PF.

Mol Oncol. 2015 Mar;9(3):545-54. doi: 10.1016/j.molonc.2014.10.010. Epub 2014 Oct 28.

15.

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.

Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 4.

16.

Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics.

Ambros IM, Brunner C, Abbasi R, Frech C, Ambros PF.

Front Oncol. 2014 Aug 12;4:202. doi: 10.3389/fonc.2014.00202. eCollection 2014.

17.

DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies.

Schmidt WM, Uddin MH, Dysek S, Moser-Thier K, Pirker C, Höger H, Ambros IM, Ambros PF, Berger W, Bittner RE.

PLoS Genet. 2011 Apr;7(4):e1002042. doi: 10.1371/journal.pgen.1002042. Epub 2011 Apr 14.

18.

A multilocus technique for risk evaluation of patients with neuroblastoma.

Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF.

Clin Cancer Res. 2011 Feb 15;17(4):792-804. doi: 10.1158/1078-0432.CCR-10-0830.

19.

Free DNA in the blood serum can unmask MYCN amplified tumors.

Ambros PF, Ambros IM.

Pediatr Blood Cancer. 2009 Sep;53(3):306-7. doi: 10.1002/pbc.22116. No abstract available.

PMID:
19489051
20.

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.

Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM.

Br J Cancer. 2009 May 5;100(9):1471-82. doi: 10.1038/sj.bjc.6605014.

21.

Pathology of peripheral neuroblastic tumors: significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma.

Tornóczky T, Semjén D, Shimada H, Ambros IM.

Pathol Oncol Res. 2007;13(4):269-75. Epub 2007 Dec 25. Review.

22.

Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea.

Narath R, Ambros IM, Kowalska A, Bozsaky E, Boukamp P, Ambros PF.

Genes Chromosomes Cancer. 2007 Feb;46(2):130-42.

PMID:
17106870
23.
24.

Treatment complications in neuroblastoma patients: lessons from screening studies.

Kerbl R, Urban CE, Zotter H, Dornbusch HJ, Ladenstein R, Ambros IM, Ambros PF.

J Clin Oncol. 2006 Jul 20;24(21):e41. No abstract available.

PMID:
16849741
25.

Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients.

Strenger V, Kerbl R, Dornbusch HJ, Ladenstein R, Ambros PF, Ambros IM, Urban C.

Pediatr Blood Cancer. 2007 May;48(5):504-9.

PMID:
16732582
26.

DEC1 expression in 1p-aberrant oligodendroglial neoplasms.

Preusser M, Birner P, Ambros IM, Ambros PF, Budka H, Harris AL, Hainfellner JA.

Histol Histopathol. 2005 Oct;20(4):1173-7. doi: 10.14670/HH-20.1173.

PMID:
16136500
27.

Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications.

Birner P, Preusser M, Gelpi E, Berger J, Gatterbauer B, Ambros IM, Ambros PF, Acker T, Plate KH, Harris AL, Hainfellner JA.

Clin Cancer Res. 2004 Oct 1;10(19):6567-71.

28.

Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors.

Kerbl R, Urban CE, Ambros IM, Dornbusch HJ, Schwinger W, Lackner H, Ladenstein R, Strenger V, Gadner H, Ambros PF.

J Clin Oncol. 2003 Nov 15;21(22):4228-34.

PMID:
14615452
29.

Disseminated tumor cells in the bone marrow - chances and consequences of microscopical detection methods.

Ambros PF, Mehes G, Ambros IM, Ladenstein R.

Cancer Lett. 2003 Jul 18;197(1-2):29-34. Review.

PMID:
12880956
30.
31.

Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.

Gelpi E, Ambros IM, Birner P, Luegmayr A, Drlicek M, Fischer I, Kleinert R, Maier H, Huemer M, Gatterbauer B, Anton J, Rössler K, Budka H, Ambros PF, Hainfellner JA.

Mod Pathol. 2003 Jul;16(7):708-15.

32.

Quality assessment of genetic markers used for therapy stratification.

Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, Couturier J, Darnfors C, Delattre O, Freeman-Edward J, Gambini C, Gross N, Hattinger CM, Luegmayr A, Lunec J, Martinsson T, Mazzocco K, Navarro S, Noguera R, O'Neill S, Potschger U, Rumpler S, Speleman F, Tonini GP, Valent A, Van Roy N, Amann G, De Bernardi B, Kogner P, Ladenstein R, Michon J, Pearson AD, Ambros PF.

J Clin Oncol. 2003 Jun 1;21(11):2077-84.

PMID:
12775732
33.

Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes.

Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros PF, Ambros IM, Bredel M, Oberhuber G, Rössler K, Budka H, Harris AL, Hainfellner JA.

Brain Pathol. 2003 Apr;13(2):133-43.

PMID:
12744467
34.

[Detection, quantification and characterization of disseminated tumor cells].

Ambros PF, Méhes G, Ambros IM, Luegmayr A, Ladenstein R, Gadner H.

Acta Med Austriaca Suppl. 2002;59:58-61. German.

PMID:
12506762
35.

Genetic changes of two Wilms tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance.

Stock C, Ambros IM, Lion T, Zoubek A, Amann G, Gadner H, Ambros PF.

Cancer Genet Cytogenet. 2002 Jun;135(2):128-38. Review.

PMID:
12127397
36.
37.

Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups.

Ambros IM, Hata J, Joshi VV, Roald B, Dehner LP, Tüchler H, Pötschger U, Shimada H.

Cancer. 2002 Mar 1;94(5):1574-83.

38.

Neuroblastoma with focal MYCN amplification and bone marrow infiltration: a staging and treatment dilemma.

Kerbl R, Ambros IM, Ambros PF, Lackner H, Dornbusch HJ, Urban CE.

Med Pediatr Oncol. 2002 Feb;38(2):109-11. No abstract available.

PMID:
11813175
39.

Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines.

Ambros PF, Ambros IM; SIOP Europe Neuroblastoma Pathology, Biology, and Bone Marrow Group.

Med Pediatr Oncol. 2001 Dec;37(6):492-504.

PMID:
11745887
40.

Prognostic significance of DNA di-tetraploidy in neuroblastoma.

Ladenstein R, Ambros IM, Pötschger U, Amann G, Urban C, Fink FM, Schmitt K, Jones R, Slociak M, Schilling F, Ritter J, Berthold F, Gadner H, Ambros PF.

Med Pediatr Oncol. 2001 Jan;36(1):83-92.

PMID:
11464912
41.

Absence of somatostatin receptor expression in vivo is correlated to di- or tetraploid 1p36-deleted neuroblastomas.

Schilling FH, Ambros PF, Bihl H, Martinsson T, Ambros IM, Borgström P, Jacobsson H, Falkmer UG, Treuner J, Kogner P.

Med Pediatr Oncol. 2001 Jan;36(1):56-60.

PMID:
11464907
42.

Automatic detection and genetic profiling of disseminated neuroblastoma cells.

Méhes G, Luegmayr A, Hattinger CM, Lörch T, Ambros IM, Gadner H, Ambros PF.

Med Pediatr Oncol. 2001 Jan;36(1):205-9.

PMID:
11464886
43.

Neuroblastoma cells provoke Schwann cell proliferation in vitro.

Ambros IM, Attarbaschi A, Rumpler S, Luegmayr A, Turkof E, Gadner H, Ambros PF.

Med Pediatr Oncol. 2001 Jan;36(1):163-8.

PMID:
11464875
44.

Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.

Ambros PF, Ambros IM, Kerbl R, Luegmayr A, Rumpler S, Ladenstein R, Amann G, Kovar H, Horcher E, De Bernardi B, Michon J, Gadner H.

Med Pediatr Oncol. 2001 Jan;36(1):1-4.

PMID:
11464855
45.
46.

Unequivocal identification of disseminated tumor cells in the bone marrow by combining immunological and genetic approaches--functional and prognostic information.

Ambros PF, Méhes G, Hattinger C, Ambros IM, Luegmayr A, Ladenstein R, Gadner H.

Leukemia. 2001 Feb;15(2):275-7. No abstract available.

47.

Combined (111)In-pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblastoma provides prognostic information.

Schilling FH, Bihl H, Jacobsson H, Ambros PF, Martinsson T, Borgström P, Schwarz K, Ambros IM, Treuner J, Kogner P.

Med Pediatr Oncol. 2000 Dec;35(6):688-91.

PMID:
11107147
48.

Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors.

Hattinger CM, Rumpler S, Strehl S, Ambros IM, Zoubek A, Pötschger U, Gadner H, Ambros PF.

Genes Chromosomes Cancer. 1999 Mar;24(3):243-54.

PMID:
10451705
49.

The International Neuroblastoma Pathology Classification (the Shimada system).

Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP.

Cancer. 1999 Jul 15;86(2):364-72.

PMID:
10421273
50.

Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.

Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B.

Cancer. 1999 Jul 15;86(2):349-63.

PMID:
10421272

Supplemental Content

Loading ...
Support Center